Core Viewpoint - A class action lawsuit has been filed against James Hardie Industries plc for securities fraud, following a significant stock drop attributed to potential violations of federal securities laws [2][4]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Northern District of Illinois, asserting claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in James Hardie common stock [4]. - Investors have until December 23, 2025, to request to be appointed to lead the case [4]. Group 2: Company Background - James Hardie is a producer and marketer of high-performance fiber cement building solutions, primarily used in external siding for the residential building industry in the U.S. and Canada [5]. Group 3: Allegations of Misrepresentation - During the relevant period, James Hardie claimed that its North American fiber cement segment showed "inherent strength" and "underlying momentum," while in reality, sales were driven by inventory loading rather than sustainable customer demand [6]. - The company reported a 12% decline in North American fiber cement sales during the quarter, revealing that customers were destocking to return to normal inventory levels [7]. Group 4: Stock Performance - Following the revelation of declining sales, James Hardie's stock price fell by $9.79 per share, a decrease of over 34%, from $28.43 on August 19, 2025, to $18.64 on August 20, 2025 [7]. Group 5: Management Changes - On November 17, 2025, it was announced that Rachel Wilson would step down from her role as CFO [8].

Core Viewpoint - Jefferies Financial Group Inc. and its trade finance arm, Point Bonita Capital, are under investigation for potential violations of federal securities laws following a probe by the SEC related to their exposure to First Brands Group, which filed for bankruptcy in September 2025 [1][5]. Group 1: Investigation Details - The SEC is investigating whether Jefferies provided adequate information to investors regarding their exposure to the auto business, which had $12 billion in debt at the time of bankruptcy [5]. - Bleichmar Fonti & Auld LLP is conducting an investigation into whether Jefferies and Point Bonita made materially false and misleading statements to investors concerning their significant exposure to First Brands [6]. Group 2: Financial Impact - On October 8, 2025, Jefferies disclosed approximately $715 million in exposure to First Brands' receivables, which constituted about 25% of Point Bonita's trade finance portfolio [4]. - Following this announcement, Jefferies' stock price dropped by $4.66 per share, or approximately 8%, from $59.10 on October 7, 2025, to $54.44 on October 8, 2025 [4]. Group 3: Company Background - Jefferies is an investment banking and capital markets firm, with Point Bonita Capital serving as its trade finance arm [3]. - Both Jefferies and Point Bonita were closely associated with First Brands Group, an auto parts supplier that went bankrupt [3].

Core Viewpoint - Inspire Medical Systems, Inc. is facing a class action lawsuit for securities fraud following a significant drop in stock price attributed to alleged misrepresentations regarding the launch of its Inspire V device [1][3]. Group 1: Lawsuit Details - A class action lawsuit has been filed against Inspire Medical Systems and certain senior executives for securities fraud, with investors encouraged to contact BFA Law by January 5, 2026 [1][3]. - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, and is pending in the U.S. District Court for the District of Minnesota [3]. Group 2: Product and Market Issues - Inspire develops an implantable medical device for sleep apnea treatment, with the latest version, Inspire V, receiving FDA approval on August 2, 2024 [4]. - Despite assurances from Inspire regarding the readiness for the launch of Inspire V, the company allegedly failed to prepare clinicians and payors adequately, leading to delays in adoption and weak demand due to excess inventory of older devices [5][6]. Group 3: Stock Price Impact - On August 4, 2025, Inspire disclosed an "elongated timeframe" for the Inspire V launch and reduced its 2025 earnings per share guidance by over 80%, causing the stock price to drop by $42.04, or more than 32%, from $129.95 to $87.91 per share [7][8].

FCX SHAREHOLDERS: Freeport-McMoRan Inc. Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law by January 12December 01, 2025 3:18 PM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - December 1, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Freeport-McMoRan Inc. (NYSE: FCX) and certain of the Company's senior executives for securities fraud after significan ...

Core Viewpoint - A class action lawsuit has been filed against Synopsys, Inc. for securities fraud, following a significant drop in stock price attributed to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Northern District of California, titled Kim v. Synopsys, Inc., et al., No. 3:25-cv-09410 [3]. - Investors have until December 30, 2025, to request to be appointed to lead the case [3]. Group 2: Company Performance - Synopsys provides design automation software products, with its Design IP segment being the fastest-growing, increasing from 25% of revenue in 2022 to 31% in 2024 [4]. - The company reported Q3 2025 results showing a revenue decline in the Design IP segment to $425.9 million, a 7.7% decrease year-over-year, and a net income of $242.5 million, down 43% year-over-year [6]. Group 3: Market Reaction - Following the Q3 2025 results announcement, Synopsys stock fell nearly 36%, from $604.37 per share to $387.78 per share [6]. - The decline was attributed to revelations that Design IP customers required more customization, impacting the business model and economics of the segment [5][6].

MLTX SHAREHOLDERS: MoonLake Immunotherapeutics Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law by December 15December 01, 2025 3:18 PM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - December 1, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the f ...

Core Viewpoint - CarMax, Inc. is facing a class action lawsuit for securities fraud following a significant drop in stock price attributed to misleading statements regarding demand and financial performance [2][4][5]. Group 1: Lawsuit Details - A class action lawsuit has been filed against CarMax and its senior executives for securities fraud, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [4]. - Investors have until January 2, 2026, to request to lead the case, which is pending in the U.S. District Court for the District of Maryland [4]. - The lawsuit alleges that CarMax misled investors about the sustainability of demand for its vehicles, particularly in light of U.S. tariffs that temporarily boosted sales [5]. Group 2: Financial Performance - CarMax reported disappointing financial results for Q2 of fiscal year 2026, including a 5.4% decline in retail used unit sales, a 6.3% decline in comparable store used unit sales, and a 2.2% decline in wholesale units [7]. - The company's net income for Q2 was approximately $95.4 million, down from $132.8 million in the previous year [7]. - The decline in sales was attributed to a "pull forward" in demand due to the announcement of tariffs, which led to a significant stock price drop of $11.45 per share, or roughly 20% [8]. Group 3: Executive Changes - The unexpected departure of CEO Bill Nash on November 6, 2025, has raised concerns about the company's management and its assessment of car loan portfolios [6]. - Following the announcement of Nash's departure and a weak preliminary Q3 outlook, CarMax's stock dropped over 24% [8].

Core Viewpoint - A class action lawsuit has been filed against Stride, Inc. for securities fraud, alleging that the company misled investors about its business performance, leading to significant stock price drops [1][3]. Company Overview - Stride, Inc. is an education technology company that provides an online platform to students across the U.S. [4]. Allegations of Fraud - The lawsuit claims that Stride inflated enrollment numbers by retaining "ghost students," failed to comply with employee background checks and licensure laws, and provided a poor customer experience that resulted in higher withdrawal rates and lower conversion rates [4][5]. Stock Price Impact - Following the allegations, Stride's stock dropped by $18.60 per share (over 11%) from $158.36 on September 12, 2025, to $139.76 on September 15, 2025 [5]. - On October 28, 2025, Stride admitted to issues with customer experience, leading to an estimated 10,000-15,000 fewer enrollments, which caused the stock to plummet by $83.48 per share (over 54%) from $153.53 to $70.05 on October 29, 2025 [6]. Legal Proceedings - Investors have until January 12, 2026, to request to be appointed to lead the case in the U.S. District Court for the Eastern District of Virginia [3]. - The lawsuit is filed under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. Investor Actions - Investors in Stride are encouraged to seek legal options and submit their information to the law firm handling the case [2][7].

Core Viewpoint - Emerging Growth Research maintains a Buy-Extended rating for SBC Medical Group Holdings, Inc. with a 12-month price target of $9.00, indicating significant upside potential from its recent closing price of $3.57 on November 28, 2025 [1][2]. Financial Performance - Q3:25 revenue was $43.4 million, flat sequentially compared to Q2:25, but down 18% year-over-year due to changes in franchising fee structures. Management expects stabilization to continue through Q1:26 before returning to historical growth rates [6]. - Operating profit increased to $15.9 million in Q3:25, up from $13.8 million in Q3:24 and $14.6 million sequentially in Q2:25, reflecting effective cost management despite revenue pressures [6]. Growth and Expansion - The company added 34 new clinic locations year-over-year, reaching a total of 258 clinics, and annual customer visits grew to 6.5 million with a 72% repeat rate. Average revenue per visit increased to $298 in Q3:25 from $275 in Q1:25 [6]. - Management anticipates revenue will resume its historical compound annual growth rate (CAGR) of +10% to +15% starting in 2026, supported by domestic organic growth and plans to expand from 258 to 1,000 clinics over the next ten years, along with strategic mergers and acquisitions in Japan, Southeast Asia, and the United States [6]. Financial Position - SBC ended Q3:25 with a strong balance sheet, holding $127 million in cash, $83 million in accounts receivable, and $15 million in prepaid expenses, against only $21 million in long-term debt. Net cash represents approximately 40% of the company's current market capitalization [6]. - The firm's discounted cash flow (DCF) analysis indicates a fair value of $8.88 per share, rounded to $9.00, with a sensitivity range of $7.33 to $12.51 per share based on terminal growth and discount rate assumptions [5]. Market Position - SBC operates a franchise-based model that generates gross margins of 70%-75% with strong cash conversion, positioning it as an attractive consolidator in the fragmented global cosmetic treatment industry [4]. - The company became a Russell 3000 constituent in June 2025 and is exploring additional liquidity initiatives, including potential share buybacks and a dividend program [6].

Core Viewpoint - GR Silver Mining Ltd. has amended its agreement with Research Capital Corporation and Red Cloud Securities Inc. to increase the size of its bought-deal offering, raising a total of $17,500,200 through the sale of 58,334,000 units at $0.30 each [1][10]. Group 1: Offering Details - Each unit consists of one common share and one-half of a common share purchase warrant, with each whole warrant allowing the purchase of one common share at an exercise price of $0.42 for 36 months [2]. - The net proceeds will be allocated to advancing the Plomosas Project in Mexico, working capital, and general corporate purposes [3]. - The Underwriters have an option to increase the offering size by up to 3,999,333 units for the LIFE Offering and 4,333,500 units for the Private Placement Offering, potentially raising total gross proceeds to $20,000,049.90 if fully exercised [4]. Group 2: Regulatory and Legal Framework - The LIFE Offering will be conducted under the 'listed issuer financing exemption' and will be available in all Canadian provinces except Quebec, as well as in other qualifying jurisdictions, including the United States [5]. - The Private Placement Offering will be available to accredited investors in Canada and other jurisdictions where it can be lawfully made, with a statutory hold period of four months and one day from closing [7]. - The closing of the offerings is anticipated around the week of December 15, 2025, subject to necessary regulatory approvals [8]. Group 3: Financial Terms - The Underwriters will receive a cash commission of 6.0% of the aggregate gross proceeds and broker warrants equal to 6.0% of the units sold, with each broker warrant allowing the purchase of one unit at the offering price for 36 months [9].